arrow
C

Cyrielle Gilletta

Sorbonne Universite
H指数:23
被引数:1,776

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of bowel urgency, disease activity and disability in patients with inflammatory bowel disease: A cross-sectional study from the GETAID

炎症性肠病患者肠道急迫感、疾病活动度与残疾的相关性:一项来自GETAID的横断面研究

2026-08-010
PRE
Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study

粒细胞和单核细胞吸附性单采(ADACOLUMN®)在难治性炎症性肠病患者中的真实世界经验:一项回顾性多中心队列研究

2026-07-010
PRE
Rationale and design of the AlloFIST trial: a phase I/IIa study to evaluate dose escalation of allogeneic adipose-derived stroma/stem cells for the treatment of Crohn's fistula

AlloFIST试验的原理与设计:一项评估同种异体脂肪来源基质/干细胞治疗克罗恩病瘘管剂量递增的I/IIa期研究

2025-12-290
OA
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID

皮下注射维多利珠单抗剂量强化在炎症性肠病患者中的应用:GETAID组织的OPTI-VEDO多中心研究

2025-09-010
PRE
A randomized controlled trial of antibiotics targeting adherent and invasive Escherichia coli versus placebo in Crohn's disease: the TEOREM trial

针对黏附侵袭性大肠杆菌的抗生素与安慰剂在克罗恩病中的随机对照试验:TEOREM试验。J. Crohns Colitis 19, jjaf093

2025-07-012
PRE
PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission

IBD缓解期患者从静脉给药途径转换为皮下给药途径1年后英夫利昔单抗的持续疗效与安全性

2025-05-190
PRE
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study

乌帕替尼诱导治疗223例克罗恩病患者的有效性与安全性:一项GETAID多中心队列研究

2025-03-042
OAAI
Efficacy and safety of a second JAK inhibitor in Ulcerative Colitis: J2J multicenter cohort
2025-01-220
PRE
Effectiveness and Safety of Upadacitinib Induction Therapy in Real-World Setting for 234 Patients with Crohn's Disease: A GETAID Multicentre Cohort Study
2025-01-220
PRE
Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study
2025-01-220
PRE
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study
2024-12-010
PRE
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

炎症性肠病患者对阿达木单抗的偏好: 来自GETAID的一项全国性研究

2024-08-072
OAAI
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID
2023-12-016
OAAI
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif
2023-08-012
OAAI
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID
2023-03-296
OA